Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 52

1.

Up-regulated MSI2 is associated with more aggressive chronic myeloid leukemia.

Kaeda J, Ringel F, Oberender C, Mills K, Quintarelli C, Pane F, Koschmieder S, Slany R, Schwarzer R, Saglio G, Hemmati P, van Lessen A, Amini L, Gresse M, Vagge E, Burmeister T, Serra A, Carson A, Schwarz M, Westermann J, Jundt F, Dörken B, le Coutre P.

Leuk Lymphoma. 2015 Jul;56(7):2105-13. doi: 10.3109/10428194.2014.981175. Epub 2015 Jan 23.

PMID:
25363400
2.

Eosinophils and megakaryocytes support the early growth of murine MOPC315 myeloma cells in their bone marrow niches.

Wong D, Winter O, Hartig C, Siebels S, Szyska M, Tiburzy B, Meng L, Kulkarni U, Fähnrich A, Bommert K, Bargou R, Berek C, Chu VT, Bogen B, Jundt F, Manz RA.

PLoS One. 2014 Oct 1;9(10):e109018. doi: 10.1371/journal.pone.0109018. eCollection 2014.

3.

Notch pathway inhibition controls myeloma bone disease in the murine MOPC315.BM model.

Schwarzer R, Nickel N, Godau J, Willie BM, Duda GN, Schwarzer R, Cirovic B, Leutz A, Manz R, Bogen B, Dörken B, Jundt F.

Blood Cancer J. 2014 Jun 13;4:e217. doi: 10.1038/bcj.2014.37.

4.

PAX5 overexpression is not enough to reestablish the mature B-cell phenotype in classical Hodgkin lymphoma.

Dimitrova L, Seitz V, Hecht J, Lenze D, Hansen P, Szczepanowski M, Ma L, Oker E, Sommerfeld A, Jundt F, Klapper W, Hummel M.

Leukemia. 2014 Jan;28(1):213-6. doi: 10.1038/leu.2013.211. Epub 2013 Jul 11. No abstract available.

PMID:
23842424
5.

A novel mouse model for multiple myeloma (MOPC315.BM) that allows noninvasive spatiotemporal detection of osteolytic disease.

Hofgaard PO, Jodal HC, Bommert K, Huard B, Caers J, Carlsen H, Schwarzer R, Schünemann N, Jundt F, Lindeberg MM, Bogen B.

PLoS One. 2012;7(12):e51892. doi: 10.1371/journal.pone.0051892. Epub 2012 Dec 20.

6.

Pathogenic long-lived plasma cells and their survival niches in autoimmunity, malignancy, and allergy.

Winter O, Dame C, Jundt F, Hiepe F.

J Immunol. 2012 Dec 1;189(11):5105-11. doi: 10.4049/jimmunol.1202317. Review.

7.

Notch is an essential upstream regulator of NF-κB and is relevant for survival of Hodgkin and Reed-Sternberg cells.

Schwarzer R, Dörken B, Jundt F.

Leukemia. 2012 Apr;26(4):806-13. doi: 10.1038/leu.2011.265. Epub 2011 Sep 27.

PMID:
21946908
8.

Eukaryotic initiation factor 2alpha phosphorylation is required for B-cell maturation and function in mice.

Mielke N, Schwarzer R, Calkhoven CF, Kaufman RJ, Dörken B, Leutz A, Jundt F.

Haematologica. 2011 Sep;96(9):1261-8. doi: 10.3324/haematol.2011.042853. Epub 2011 May 12.

9.

Notch and NF-κB signaling pathways in the biology of classical Hodgkin lymphoma.

Schwarzer R, Jundt F.

Curr Mol Med. 2011 Apr;11(3):236-45. Review.

PMID:
21375490
10.

High-level expression of Mastermind-like 2 contributes to aberrant activation of the NOTCH signaling pathway in human lymphomas.

Köchert K, Ullrich K, Kreher S, Aster JC, Kitagawa M, Jöhrens K, Anagnostopoulos I, Jundt F, Lamprecht B, Zimber-Strobl U, Stein H, Janz M, Dörken B, Mathas S.

Oncogene. 2011 Apr 14;30(15):1831-40. doi: 10.1038/onc.2010.544. Epub 2010 Nov 29.

PMID:
21119597
11.

Aberrant expression of the Th2 cytokine IL-21 in Hodgkin lymphoma cells regulates STAT3 signaling and attracts Treg cells via regulation of MIP-3alpha.

Lamprecht B, Kreher S, Anagnostopoulos I, Jöhrens K, Monteleone G, Jundt F, Stein H, Janz M, Dörken B, Mathas S.

Blood. 2008 Oct 15;112(8):3339-47. doi: 10.1182/blood-2008-01-134783. Epub 2008 Aug 6.

12.

IkappaBalpha is required for marginal zone B cell lineage development.

Ellinghaus U, Rupec RA, Pabst O, Ignatius R, Förster R, Dörken B, Jundt F.

Eur J Immunol. 2008 Aug;38(8):2096-105. doi: 10.1002/eji.200838254.

13.

Notch inhibition blocks multiple myeloma cell-induced osteoclast activation.

Schwarzer R, Kaiser M, Acikgoez O, Heider U, Mathas S, Preissner R, Sezer O, Doerken B, Jundt F.

Leukemia. 2008 Dec;22(12):2273-7. doi: 10.1038/leu.2008.138. Epub 2008 Jun 5. No abstract available.

PMID:
18528422
14.

Aberrant expression of Notch1 interferes with the B-lymphoid phenotype of neoplastic B cells in classical Hodgkin lymphoma.

Jundt F, Acikgöz O, Kwon SH, Schwarzer R, Anagnostopoulos I, Wiesner B, Mathas S, Hummel M, Stein H, Reichardt HM, Dörken B.

Leukemia. 2008 Aug;22(8):1587-94. doi: 10.1038/leu.2008.101. Epub 2008 May 1.

PMID:
18449208
15.

Notch signaling in leukemias and lymphomas.

Jundt F, Schwarzer R, Dörken B.

Curr Mol Med. 2008 Feb;8(1):51-9. Review.

PMID:
18289013
16.

Loss of bHLH transcription factor E2A activity in primary effusion lymphoma confers resistance to apoptosis.

Lietz A, Janz M, Sigvardsson M, Jundt F, Dörken B, Mathas S.

Br J Haematol. 2007 May;137(4):342-8.

PMID:
17456056
17.

Intrinsic inhibition of transcription factor E2A by HLH proteins ABF-1 and Id2 mediates reprogramming of neoplastic B cells in Hodgkin lymphoma.

Mathas S, Janz M, Hummel F, Hummel M, Wollert-Wulf B, Lusatis S, Anagnostopoulos I, Lietz A, Sigvardsson M, Jundt F, Jöhrens K, Bommert K, Stein H, Dörken B.

Nat Immunol. 2006 Feb;7(2):207-15. Epub 2005 Dec 20.

PMID:
16369535
18.

Elevated NF-kappaB p50 complex formation and Bcl-3 expression in classical Hodgkin, anaplastic large-cell, and other peripheral T-cell lymphomas.

Mathas S, Jöhrens K, Joos S, Lietz A, Hummel F, Janz M, Jundt F, Anagnostopoulos I, Bommert K, Lichter P, Stein H, Scheidereit C, Dörken B.

Blood. 2005 Dec 15;106(13):4287-93. Epub 2005 Aug 25.

19.

Charged meson rapidity distributions in central Au+Au collisions at square root(sNN) = 200 GeV.

Bearden IG, Beavis D, Besliu C, Budick B, Bøggild H, Chasman C, Christensen CH, Christiansen P, Cibor J, Debbe R, Enger E, Gaardhøje JJ, Germinario M, Hagel K, Hansen O, Holm A, Holme AK, Ito H, Jipa A, Jundt F, Jørdre JI, Jørgensen CE, Karabowicz R, Kim EJ, Kozik T, Larsen TM, Lee JH, Lee YK, Løvhøiden G, Majka Z, Makeev A, Mikelsen M, Murray M, Natowitz J, Nielsen BS, Norris J, Olchanski K, Ouerdane D, Płaneta R, Rami F, Ristea C, Röhrich D, Samset BH, Sandberg D, Sanders SJ, Sheetz RA, Staszel P, Tveter TS, Videaek F, Wada R, Yin Z, Zgura IS; BRAHMS Collaboration.

Phys Rev Lett. 2005 Apr 29;94(16):162301. Epub 2005 Apr 28.

PMID:
15904216
20.

A rapamycin derivative (everolimus) controls proliferation through down-regulation of truncated CCAAT enhancer binding protein {beta} and NF-{kappa}B activity in Hodgkin and anaplastic large cell lymphomas.

Jundt F, Raetzel N, Müller C, Calkhoven CF, Kley K, Mathas S, Lietz A, Leutz A, Dörken B.

Blood. 2005 Sep 1;106(5):1801-7. Epub 2005 May 10.

Supplemental Content

Loading ...
Support Center